MIT researchers repurpose cancer compound to treat PKD
Autosomal dominant polycystic kidney disease affects more than 12 million people globally
Read More
Tag: Massachusetts Institute of Technology; MIT; Parkinson’s disease; neurodegenerative disorders
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
- Gedeon Richter UK takes over UK rights to cariprazine
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
